Two weeks after Matthew Spencer received a steroid injection for back pain, he was feeling even worse, suffering from an aching head, stiff neck, nausea, and stabbing back pain. Finally, he drove himself to the emergency room.
Doctors suspected fungal meningitis. Test results were not definitive, but the steroid had been made by the Framingham pharmacy linked to an expanding national outbreak of the rare and dangerous disease.
After seven days in the hospital, the part-time mayor of Somersworth, N.H., was back home Tuesday, where a machine pumps a powerful antifungal medication into his veins five hours a day. The drug causes liver inflammation, and for the first 30 minutes of each treatment, images flicker across his eyes.
Spencer’s situation illustrates many of the challenges public health officials, physicians, and patients are grappling with in the outbreak: Fungal meningitis is usually exceedingly difficult to diagnose, and the treatment is risky and arduous.
“It’s like going to a supermarket and buying a bottle of water and finding out it’s Windex,’’ said Spencer, 42, about receiving a steroid potentially contaminated with fungus. “It’s unfortunate.’’
Spencer waited more than two weeks after his epidural injection on Sept. 19 to seek medical care. In part, that was because he and his doctors attributed his initial symptoms to the injection itself, which he received to ease pain from spinal stenosis caused by an old Coast Guard injury.
“I know people who have been called” by health officials “and still haven’t gone to get tested,’’ Spencer said in a telephone interview. “I want to encourage them to do that.’’
Doctors often have to make the diagnosis without laboratory test results positively identifying fungus in the spinal fluid, as they did with Spencer.
Dr. Paul Sax, an infectious disease specialist at Brigham and Women’s Hospital in Boston, said spinal fluid often is negative for fungal contamination, because fungus grows very slowly and common tests are not always sensitive enough to detect it. Repeated testing is often required, and even then, spinal fluid sometimes never shows up positive.
As a result, the Centers for Disease Control and Prevention is advising doctors on conference calls and its website to start treatment when patients exhibit meningitis symptoms, have a high white blood cell count, and have been exposed to sterile injectable steroids made by New England Compounding Center.
On Monday, the Food and Drug Administration expanded its advice to health care providers, saying they should evaluate patients who have received any injectable drug made by the company and who have symptoms of meningitis or infection at the site of a joint injection.
“Fungal meningitis is a very serious problem,’’ Sax said. Treatment should be started before “definitive evidence if you have a suspected case, because the longer you wait, the longer the infection has to become severe.’’
The CDC, however, has stopped short of recommending that patients without symptoms receive intravenous therapy, at least for now, because the risks include liver and kidney damage. In the case of liver inflammation caused by the antifungal voriconazole, it is usually reversible if the drug is stopped before the symptoms are too severe, Sax said.
Some patients with severe cases will be on intravenous drugs for months. No one knows the optimal length of therapy because fungal meningitis is so rare, doctors said.
“The burden of treatment is unclear; therapy could go on for years,’’ said Dr. James P. Rathmell, chief of pain medicine at Massachusetts General Hospital, who earlier this week was on a panel in Washington, D.C., discussing the outbreak. Doctors “just don’t know, because this is a new phenomenon,’’ he said.
The CDC said the number of infected patients grew to 233 Tuesday; 15 patients have died. The FDA has expanded the potentially contaminated drugs to include two injectable steroids made by New England Compounding, though most patients infected received injections of methylprednisolone acetate, and a solution used during heart surgery. On Tuesday, the agency sent criminal investigators to the offices of the company, suggesting the growing seriousness of the situation.
The outbreak has focused attention on a little-known corner of drug-making called compounding that some critics argue has fallen through the regulatory cracks.
Jeffrey Montpetit, a lawyer in Minneapolis, filed a class action lawsuit last week on behalf of Minnesota residents injected with potentially tainted steroids. Continued...